Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.47 |
| ▸ | SLC9A1 | P19634 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19656844 | 0.81 | SLC9A1 (0.61) | SLC9A1MEN1ALDH1A1KMT2A | |
| SCHEMBL3077834 | 0.78 | HPGD (0.50) | HSD17B1MEN1ALDH1A1KMT2A | |
| SCHEMBL19657077 | 0.77 | SLC9A1 (0.64) | SLC9A1ALDH1A1NPSR1 | |
| SCHEMBL23566022 | 0.76 | NQO2 (0.50) | ALDH1A1NQO2 | |
| SCHEMBL7352974 | 0.76 | NQO2 (0.65) | SLC9A1ALDH1A1NQO2 | |
| SCHEMBL22931244 | 0.73 | ALDH1A1 (0.67) | SLC9A1ALDH1A1 | |
| Nitrafudam SCHEMBL121333 | 0.73 | SLC9A1 (0.66) | SLC9A1MEN1ALDH1A1KMT2A | |
| SCHEMBL395347 | 0.72 | NQO2 (0.63) | SLC9A1ALDH1A1NQO2 | |
| SCHEMBL31337366 | 0.69 | LMNA (0.72) | MEN1ALDH1A1KMT2ANPSR1 | |
| SCHEMBL19629253 | 0.68 | SLC9A1 (0.63) | SLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10314820-B2 | Imidazole-based heterocyclic compounds | PROCOMCURE BIOTECH GMBH (AT) | 2019-06-11 | — | — | US | disclosed |
| US-20170340613-A1 | Novel Imidazole-Based Heterocyclic Compounds | PROCOMCURE BIOTECH GMBH (AT) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340613-A1 | Novel Imidazole-Based Heterocyclic Compounds | SLC11A2, MIF, NISCH | HSD17B1 1593/4885SLC9A1 3586/4885MEN1 1989/4885 |
| US-10314820-B2 | Imidazole-based heterocyclic compounds | MIF, SLC11A2, TLR5 | HSD17B1 1237/4885SLC9A1 3248/4885MEN1 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.